Table 1. Patient and treatment characteristics.
Chart and imaging review revealed patient and treatment characteristics, summarized descriptively. Statistics are presented as median [minimum—maximum]; n (%).
| Characteristic | n=64 |
|---|---|
| Dose to tumor (Gy) | 136 [19—445] |
| Unknown | 6 |
| Dose to normal parenchyma (Gy) | 68 [12—244] |
| Unknown | 6 |
| Number of extrahepatic metastatic sites | |
| 0 | 10 (16%) |
| 1 | 16 ( 25%) |
| 2 | 17 (2 '%) |
| 3 | 15 (23%) |
| 4 | 5(7.8%) |
| 5 | 1 (1.6%) |
| TARE device | |
| Glass microspheres | 42 (66%) |
| Resin microspheres | 22 (34%) |
| Extent of disease | |
| Unilobar | 16 (25%) |
| Bilobar | 48 (75%) |
| Lung shunt fraction (%) | 3 [0–10] |
| Number of systemic therapy lines | 8 [1–19] |
| Hormone receptor st ‘us | |
| ER+ | 47 (73%) |
| PR+ | 36 (56%) |
| HEr 2 + | 11 (17%) |
| Pre-TARE laboratory values | |
| Total bilirubin (mg/dL) | 0.55 [0.20—2.50] |
| AST (units/L) | 35 [12—373] |
| ALT (units/L) | 34 [9—193] |
| Platelets (x10^9/L) | 201 [54—590] |
| Percent of normal parenchyma treated | 50 [11—83] |
| Unknown | 6 |
| Anticoagulation | 19 (30%) |